PDCD1 and thyroiditis: Similar to ipilimumab treatment, PD-1 blockade therapy can also cause a variety of irAEs including dermatitis (17%), thyroiditis (10%), hepatitis (3%), pneumonitis (3%), and colitis (2%) (76) (Table 1).